Potent, ATP-competitive Aurora kinase inhibitor (IC50
values are 3, 9 and 31 nM for Aurora C, A and B, respectively). Exhibits both in vitro
and in vivo
activity against human cancer cell lines and tumor xenograft models. Displays additive antiproliferative effects in combination with chemotherapeutics such as carboplatin
(Cat. No. 2626), gemcitabine
(Cat. No. 3259) and 5-fluorouracil
(Cat. No. 3257).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
SNS-314, a pan-Aurora kinase inhibitor, shows potent and anti-tumor activity and dosing flexibility in vivo.
Arbitrario et al.
Cancer Chemother. Pharmacol., 2010;65:707
The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model.
VanderPorten et al.
Mol.Cancer Ther., 2009;8:930
Discovery of a potent and selective Aurora kinase inhibitor.
Oslob et al.